Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic comparison of Dysport, Botox, and Xeomin in healthy males
NCT04970407Phase 1Completed
- Sponsor
- Ipsen
- Start
- Jul 2021
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of abobotulinumtoxinA in glabellar lines (3 arms), sponsored by Ipsen. Primary endpoint: Change From Baseline in Adjusted Mean (AM) Percentage (%) of CMAP Total Amplitude at Week 28. Started Jul 2021; status: completed.
02
Drugs
abobotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT04970407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04970407.